Published in J Infect Dis on January 01, 1999
Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev (2005) 5.02
In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother (2004) 1.68
Prospective cohort study of enterotoxigenic Escherichia coli infections in Argentinean children. J Clin Microbiol (1999) 1.50
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun (2002) 1.34
Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Infect Immun (2001) 1.02
From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J Med Res (2011) 1.01
Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees. Infect Immun (1999) 1.01
Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect Immun (2001) 1.01
Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect Immun (2000) 0.98
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun (2006) 0.97
Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine. Clin Diagn Lab Immunol (2001) 0.92
Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults. Infect Immun (2000) 0.90
Mucosal and systemic immune responses to chimeric fimbriae expressed by Salmonella enterica serovar typhimurium vaccine strains. Infect Immun (2000) 0.89
Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Public Health (2013) 0.86
Chloroplast targeting of FanC, the major antigenic subunit of Escherichia coli K99 fimbriae, in transgenic soybean. Plant Cell Rep (2007) 0.80
Partially assembled K99 fimbriae are required for protection. Infect Immun (2005) 0.80
Enteric disease surveillance under the AFHSC-GEIS: current efforts, landscape analysis and vision forward. BMC Public Health (2011) 0.80
Active immunization in the United States: developments over the past decade. Clin Microbiol Rev (2001) 0.80
Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC Res Notes (2016) 0.77
Ecological meltdown in predator-free forest fragments. Science (2001) 9.84
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Enzyme-linked immunosorbent assays for cholera serology. Infect Immun (1973) 6.10
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med (1991) 6.07
Typhoid fever in children aged less than 5 years. Lancet (1999) 6.00
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 4.56
Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol (1996) 4.47
Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet (1997) 4.11
Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet (1995) 3.70
Trial of calcium to prevent preeclampsia. N Engl J Med (1997) 3.69
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07
Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun (1976) 2.92
The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med (1994) 2.92
Multipractice analysis of laparoscopic cholecystectomy in 1,983 patients. Am J Surg (1992) 2.87
Field trial of oral cholera vaccines in Bangladesh. Lancet (1986) 2.85
Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence. N Engl J Med (1990) 2.85
Urachal remnant diseases: spectrum of CT and US findings. Radiographics (2001) 2.82
Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis (1985) 2.78
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol (1986) 2.77
Rapid GM1-enzyme-linked immunosorbent assay with visual reading for identification of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1983) 2.76
Molecular and biotechnological aspects of xylanases. FEMS Microbiol Rev (1999) 2.76
Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun (1998) 2.71
Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol (2000) 2.69
Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther (2014) 2.66
Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin Microbiol (1986) 2.65
The BCG controversy. A methodological and statistical reappraisal. JAMA (1983) 2.60
The burden of cholera in the slums of Kolkata, India: data from a prospective, community based study. Arch Dis Child (2005) 2.59
Cholera in India: an analysis of reports, 1997-2006. Bull World Health Organ (2010) 2.52
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development (2001) 2.43
Development of improved cholera vaccine based on subunit toxoid. Nature (1977) 2.42
Comparison of latex agglutination with established bacteriological tests for diagnosis of cerebrospinal meningitis. Lancet (1989) 2.38
An educational intervention for altering water-sanitation behaviors to reduce childhood diarrhea in urban Bangladesh. II. A randomized trial to assess the impact of the intervention on hygienic behaviors and rates of diarrhea. Am J Epidemiol (1987) 2.38
Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA (1998) 2.37
Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA (1999) 2.34
A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med (1984) 2.27
Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci (2000) 2.25
Twenty-four-hour recall, knowledge-attitude-practice questionnaires, and direct observations of sanitary practices: a comparative study. Bull World Health Organ (1987) 2.24
Mechanisms of disease and immunity in cholera: a review. J Infect Dis (1977) 2.17
Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 2.16
Serum cotinine concentration and self-reported smoking during pregnancy. Am J Epidemiol (1998) 2.15
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
Secretory immunoglobulin A and G antibodies prevent adhesion of Escherichia coli to human urinary tract epithelial cells. Infect Immun (1978) 2.13
Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis (1983) 2.08
Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect Immun (1982) 2.08
Colonization factors of enterotoxigenic Escherichia coli isolated from children with diarrhea in Argentina. J Clin Microbiol (1991) 2.06
Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun (1997) 2.01
Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J Infect Dis (1998) 2.01
Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest (1997) 1.98
Impact of measles vaccination on childhood mortality in rural Bangladesh. Bull World Health Organ (1990) 1.95
Identification of a mannose-binding pilus on Vibrio cholerae El Tor. Microb Pathog (1991) 1.94
Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med (1990) 1.93
Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol (1995) 1.89
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene (2010) 1.87
Presence of colonization factor antigens on fresh isolates of fecal Escherichia coli: a prospective study. J Infect Dis (1985) 1.87
High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. Am J Trop Med Hyg (1996) 1.86
An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis (2001) 1.86
Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl (2007) 1.84
Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand J Immunol (1977) 1.83
Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun (1991) 1.82
Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine. Lancet (1993) 1.82
Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun (1975) 1.82
Rapid detection of herpes simplex virus in clinical specimens by use of a capture biotin-streptavidin enzyme-linked immunosorbent assay. J Clin Microbiol (1984) 1.82
Characterization of monoclonal antibodies against putative colonization factors of enterotoxigenic Escherichia coli and their use in an epidemiological study. J Clin Microbiol (1993) 1.81
The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol (1998) 1.81
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer (2003) 1.80
Persistently negative tuberculin reactions: their presence among children with culture positive for Mycobacterium tuberculosis (tuberculin-negative tuberculosis). Am J Dis Child (1980) 1.78
Solitary maxillary central incisor and congenital nasal pyriform aperture stenosis. Eur J Pediatr (1998) 1.78
Comparison of open and laparoscopic live donor left lateral sectionectomy. Br J Surg (2011) 1.75
Prevalence and predictors of the prone sleep position among inner-city infants. JAMA (1998) 1.74
Endovascular treatment of intracranial vertebral artery dissections with stent placement or stent-assisted coiling. AJNR Am J Neuroradiol (2006) 1.71
Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1979) 1.70
ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis (1989) 1.66
First place--resident clinical science award 1999. Quality of life for children with obstructive sleep apnea. Otolaryngol Head Neck Surg (2000) 1.65
Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med (1983) 1.64
Quantitation of vibriocidal antibodies using agar plague techniques. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 1.63
Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis (1993) 1.63
Experimental studies on cholera immunization. 1. The response of neutralizing and vibriocidal antibodies in rabbits after immunization with culture filtrate material from V. cholerae. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.63
Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull World Health Organ (1984) 1.62
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer (2008) 1.62
The cellular function of MASH1 in autonomic neurogenesis. Neuron (1995) 1.62
Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin. Med Biol (1986) 1.61
Colonization factors of enterotoxigenic Escherichia coli isolated from children in north India. J Infect Dis (1996) 1.61
Pathogenesis of high-altitude pulmonary oedema: direct evidence of stress failure of pulmonary capillaries. Eur Respir J (1995) 1.59
Cardiac involvement in Wilson's disease--an electrocardiographic observation. J Assoc Physicians India (2004) 1.58
Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology (2008) 1.57
Apoptotic chondrocyte death in human osteoarthritis. J Rheumatol (2000) 1.56
Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J (1989) 1.56
Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity. Int Arch Allergy Appl Immunol (1975) 1.56
Skin immunization made possible by cholera toxin. Nature (1998) 1.55
Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine (1993) 1.54
Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med (1992) 1.53
The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol Appl Pharmacol (2001) 1.51